Quarterly reports of cannabis companies help raise the market

Over the last week, cannabis shares have achieved really good gains and the main reason for this was the quarterly reports issued by Tilray and especially Aurora Cannabis. The latter started the week with a stock split, exchanging ten hemp stocks for a new one.

Find out more details about the cannabis industry and read the latest cannabis news, with the Hemp.im mobile app.

Current developments on the cannabis market

Since the beginning of the coronavirus pandemic, many cannabis companies are converting and relying on deliveries. Selling cannabis online involves innovative aspects, from apps to drones.

However, in many places there are also problems with logistics, the staff is sick or in quarantine and even though the quarterly reports look good, reduced sales could tear a large hole in the balance sheets of cannabis stocks.

In addition, the management of cannabis companies is under pressure. For example, at Canopy Growth two top people have just left the company. Of course, analysts don’t know in detail whether this was due to different views on the growth of the cannabis business – or the inability to save, reduce costs, and acquire new sources of funding for the chronically depressed cannabis companies in the USA and Canada.

Government aid is still not on the cards, so investors are looking at the balance sheets for cash. At the same time, the majority of banks don’t offer loans to the cannabis industry, so everything must always be paid in cash. This attracts quite a few thieves, even if their actions mainly affect local cannabis shops, rather than the big manufacturers and blue chips on the stock exchange.

The cannabis industry is still under pressure and the rosy reports for the first quarter are probably just a piece of information from the past with little meaning for the future. Only the steady demand from cannabis consumers and hemp patients remains unchanged.

The marijuana index and performance of cannabis stocks

As already mentioned in the beginning, investors in cannabis stocks were pleased about a good bump in the week that just ended. Overall, North American stocks often rose by double digits, and the volume of day trading, especially of large companies, increased significantly.

The USA, which has lacked news this week, gained a good four percent per cannabis share on the stock exchange, which is not bad in view of the price decline that has been going on for several months.

Investors should remain cautious when investing in cannabis companies

Canopy Growth rose, like most cannabis stocks, but the gains weren’t that impressive. The stock showed no relative strength and rose from $13 to $15 (€12 to €14), which is a lot, but little compared to the overall market.

Aurora Cannabis sales increased to $53.4 million (CAD75 million), but the gross profit decreased by half, which reflects the high costs. Per total, Aurora recorded a loss of about $99.7 million (CAD 140 million).

Tilray: the loss per share of $1.73 is a good six times higher than expected! Cannabis products of Tilray were converted in the first quarter at a value of somewhat more than $50 million. In addition, the company trails estimates; sales increased clearly in relation to the previous year, but only marginally.

Aphria: Initially, its shares price fell again below the $3.25 (€3) mark, but then there was a rise in the slipstream of the Aurora figures. Consequently, investors are cautious when betting on this cannabis company.

The shares of Deutsche Cannabis AG fell slightly and probably quite unnoticed in the range of $0.54 (€0.50). This is a penny stock, which unfortunately has hardly any news to offer.

__

(Featured image by CBD-Infos-com via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in THC.GUIDE, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.